[Does oncology change its paradigm? The challenge of agnostic approval of new therapies.]
Oncology drugs have been traditionally approved for the treatment of specific cancer diseases. Recently, regulatory decisions about new cancer therapies have been taken by the Food and Drug Administration starting from biomarker data irrespective of organ site or histology. This new pattern can be defined as a "mutational model". A drug is approved and put on the market because it is active on a certain driver mutation and is approved regardless of the primary disease site, age, or gender. To face this kind of challenge in a non-disruptive way, the healthcare system should be able to anticipate these changes, so as to put in place regulatory procedures aimed at guaranteeing appropriateness and economic sustainability. The answer to this challenge should be obtained through multidisciplinary networks of health professionals (oncologists, pathologists, epidemiologists, health decision makers, etc.) supported by updated disease registries. In this way, it would be possible to gather data and evidence in real time, guaranteeing the needed governance of the system.